Show simple item record

dc.contributor.authorMikaelsdottir, Marta
dc.contributor.authorVidarsson, Brynjar
dc.contributor.authorRunarsson, Gudmundur
dc.contributor.authorBjarnadottir, Una
dc.contributor.authorOnundarson, Pall T
dc.contributor.authorSigurjonsson, Olafur E
dc.contributor.authorHalldorsdottir, Anna M
dc.date.accessioned2020-12-16T17:02:11Z
dc.date.available2020-12-16T17:02:11Z
dc.date.issued2020-11-09
dc.date.submitted2020-12
dc.identifier.citationMikaelsdottir M, Vidarsson B, Runarsson G, Bjarnadottir U, Onundarson PT, Sigurjonsson OE, Halldorsdottir AM. A comparison of platelet quality between platelets from healthy donors and hereditary hemochromatosis donors over seven-day storage. Transfusion. 2020 Nov 9. doi: 10.1111/trf.16176.en_US
dc.identifier.pmid33166431
dc.identifier.doi10.1111/trf.16176
dc.identifier.urihttp://hdl.handle.net/2336/621612
dc.descriptionTo access publisher's full text version of this article click on the hyperlink belowen_US
dc.description.abstractBackground: Therapeutic phlebotomy is the standard treatment of hereditary hemochromatosis (HH), the most common genetic disease in people of Northern European descent. Red cell concentrates from HH donors have been reported safe for transfusion, but little data is available on the storage properties of platelet concentrates from HH donors. Study design and methods: Whole blood was collected from 10 healthy individuals and 10 newly diagnosed HH patients with elevated serum ferritin. Platelet-rich plasma (PRP) was prepared and split into four 20-mL units. Platelet quality tests were performed on days 0, 1, 3, 5, and 7 of storage, including platelet aggregation (ADP, arachidonic acid, collagen, and epinephrine agonists), blood gas analysis, flow cytometry (CD41, CD42b, and CD62P expression), and ELISA (sCD40L and sCD62p in supernatant). Results: Mean serum ferritin levels were higher in HH patients than in controls (847.5 vs 45.8 ng/mL, P < .001). Overall, no difference in quality test results was observed between the two study groups over 7-day storage (P > .05), including blood gas analysis, platelet aggregation, and expression of surface (CD62p and CD42b) and secreted (sCD62P and sCD40L) activation markers. Expected alterations in metabolic (CO2 and glucose decrease, O2 and lactate increase, P < .001) and platelet activation markers (CD42b decrease, CD62P increase, P < .05) over time were observed in both groups. Conclusion: Although these findings indicate that platelets of individuals with HH are comparable to platelets from healthy donors, more extensive studies are needed before definite conclusions can be drawn.en_US
dc.description.sponsorshipLandspitali National University Hospital Research Funden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.urlhttps://onlinelibrary.wiley.com/doi/10.1111/trf.16176en_US
dc.rights© 2020 AABB.
dc.subjectBlóðflöguren_US
dc.subject.meshBlood Plateletsen_US
dc.subject.meshPlatelet Transfusionen_US
dc.titleA comparison of platelet quality between platelets from healthy donors and hereditary hemochromatosis donors over seven-day storage.en_US
dc.typeArticleen_US
dc.identifier.eissn1537-2995
dc.contributor.department1Faculty of Medicine, University of Iceland, Reykjavik, Iceland. 2Department of Hematology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland. 3Department of Immunology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland. 4The Blood Bank, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland. 5School of Science and Engineering, Reykjavik University, Reykjavik, Iceland.en_US
dc.identifier.journalTransfusionen_US
dc.rights.accessNational Consortium - Landsaðganguren_US
dc.departmentcodeHEM12
dc.departmentcodeNAF12
dc.departmentcodePTT12
dc.source.journaltitleTransfusion
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record